Adoptive cell therapy for Melanoma using tumour infiltrating lymphocytes: John Bridgeman

3 Bekeken
administrator
administrator
07/30/23

A look at the use of TIL in Melanoma and future TIL engineering strategies. John Bridgeman is the Director of Cell Therapy Research at Immetacyte Ltd

  • categorie

Laat meer zien

0 Comments Sorteer op

Geen reacties gevonden

Facebook Reacties

Volgende